Dual-target GD2/B7-H3 CAR-NK cell therapy (Beijing Biotech)

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NameDual-target GD2/B7-H3 CAR-NK cell therapy (Beijing Biotech)
Drug Alias NameEB-DTNB-NK
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Cell therapy > Source of cells > Umbilical cord blood-derivedCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionDisialoganglioside GD2 modulatorsCD276 antigen modulatorsNatural killer cell replacements
TargetsDisialoganglioside GD2CD276 antigen
Therapy Area/IndicationsGanglioneuroblastomaNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Biotech
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Biotech
Inactive CompaniesN/A
Active IndicationsGanglioneuroblastomaNeuroblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A